279 related articles for article (PubMed ID: 37306039)
1. P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial.
Guimarães PO; Franken M; Tavares CAM; Silveira FS; Antunes MO; Bergo RR; Joaquim RM; Hirai JCS; Andrade PB; Pitta FG; Mariani J; Nascimento BR; de Paula JET; Silveira MS; Costa TAO; Dall'Orto FTC; Serpa RG; Sampaio FBA; Ohe LN; Mangione FM; Furtado RHM; Sarmento-Leite R; Monfardini F; Assis SRL; Nicolau JC; Sposito AC; Lopes RD; Onuma Y; Valgimigli M; Angiolillo DJ; Serruys PW; Berwanger O; Bacal F; Lemos PA
EuroIntervention; 2023 Jul; 19(4):e323-e329. PubMed ID: 37306039
[TBL] [Abstract][Full Text] [Related]
2. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL
Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541
[TBL] [Abstract][Full Text] [Related]
3. P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials.
Song PS; Park YH; Oh JH; Song YB; Choi SH; Gwon HC; Cho DK; Rha SW; Bae JW; Jeong JO; Hahn JY;
Am J Cardiol; 2021 Jul; 150():47-54. PubMed ID: 34011436
[TBL] [Abstract][Full Text] [Related]
4. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.
Ge Z; Kan J; Gao X; Raza A; Zhang JJ; Mohydin BS; Gao F; Shao Y; Wang Y; Zeng H; Li F; Khan HS; Mengal N; Cong H; Wang M; Chen L; Wei Y; Chen F; Stone GW; Chen SL;
Lancet; 2024 May; 403(10439):1866-1878. PubMed ID: 38599220
[TBL] [Abstract][Full Text] [Related]
5. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials.
Giacoppo D; Matsuda Y; Fovino LN; D'Amico G; Gargiulo G; Byrne RA; Capodanno D; Valgimigli M; Mehran R; Tarantini G
Eur Heart J; 2021 Jan; 42(4):308-319. PubMed ID: 33284979
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial.
Song YB; Oh SK; Oh JH; Im ES; Cho DK; Cho BR; Lee JY; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC; Hahn JY
Am Heart J; 2018 Mar; 197():77-84. PubMed ID: 29447787
[TBL] [Abstract][Full Text] [Related]
7. De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a systematic review and network meta-analysis.
De Filippo O; Piroli F; Bruno F; Bocchino PP; Saglietto A; Franchin L; Angelini F; Gallone G; Rizzello G; Ahmad M; Gasparini M; Chatterjee S; De Ferrari GM; D'Ascenzo F
BMJ Evid Based Med; 2024 May; 29(3):171-186. PubMed ID: 38242567
[TBL] [Abstract][Full Text] [Related]
8. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
[TBL] [Abstract][Full Text] [Related]
9. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
Hahn JY; Song YB; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Kim J; Choi KH; Park TK; Lee JM; Yang JH; Choi JH; Choi SH; Gwon HC;
Lancet; 2018 Mar; 391(10127):1274-1284. PubMed ID: 29544699
[TBL] [Abstract][Full Text] [Related]
10. Stopping Aspirin Within 1 Month After Stenting for Ticagrelor Monotherapy in Acute Coronary Syndrome: The T-PASS Randomized Noninferiority Trial.
Hong SJ; Lee SJ; Suh Y; Yun KH; Kang TS; Shin S; Kwon SW; Lee JW; Cho DK; Park JK; Bae JW; Kang WC; Kim S; Lee YJ; Ahn CM; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK;
Circulation; 2024 Feb; 149(8):562-573. PubMed ID: 37878786
[TBL] [Abstract][Full Text] [Related]
11. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.
Kim BK; Hong SJ; Cho YH; Yun KH; Kim YH; Suh Y; Cho JY; Her AY; Cho S; Jeon DW; Yoo SY; Cho DK; Hong BK; Kwon H; Ahn CM; Shin DH; Nam CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y;
JAMA; 2020 Jun; 323(23):2407-2416. PubMed ID: 32543684
[TBL] [Abstract][Full Text] [Related]
12. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study.
Baber U; Dangas G; Cohen DJ; Gibson CM; Mehta SR; Angiolillo DJ; Pocock SJ; Krucoff MW; Kastrati A; Ohman EM; Steg PG; Badimon J; Zafar MU; Chandrasekhar J; Sartori S; Aquino M; Mehran R
Am Heart J; 2016 Dec; 182():125-134. PubMed ID: 27914492
[TBL] [Abstract][Full Text] [Related]
13. Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US.
Wang Y; Cavallari LH; Brown JD; Thomas CD; Winterstein AG
JAMA Netw Open; 2023 Apr; 6(4):e238585. PubMed ID: 37067798
[TBL] [Abstract][Full Text] [Related]
14. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.
Kim HS; Kang J; Hwang D; Han JK; Yang HM; Kang HJ; Koo BK; Rhew JY; Chun KJ; Lim YH; Bong JM; Bae JW; Lee BK; Park KW;
Lancet; 2020 Oct; 396(10257):1079-1089. PubMed ID: 32882163
[TBL] [Abstract][Full Text] [Related]
15. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.
Hahn JY; Song YB; Oh JH; Chun WJ; Park YH; Jang WJ; Im ES; Jeong JO; Cho BR; Oh SK; Yun KH; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC;
JAMA; 2019 Jun; 321(24):2428-2437. PubMed ID: 31237645
[TBL] [Abstract][Full Text] [Related]
16. An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial.
Natsuaki M; Watanabe H; Morimoto T; Yamamoto K; Obayashi Y; Nishikawa R; Ando K; Domei T; Suwa S; Ogita M; Isawa T; Takenaka H; Yamamoto T; Ishikawa T; Hisauchi I; Wakabayashi K; Onishi Y; Hibi K; Kawai K; Yoshida R; Suzuki H; Nakazawa G; Kusuyama T; Morishima I; Ono K; Kimura T
Circulation; 2024 Feb; 149(8):585-600. PubMed ID: 37994553
[TBL] [Abstract][Full Text] [Related]
17. Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and design.
Kim C; Hong SJ; Shin DH; Kim BK; Ahn CM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
Am Heart J; 2019 Jun; 212():45-52. PubMed ID: 30933857
[TBL] [Abstract][Full Text] [Related]
18. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS.
Baber U; Dangas G; Angiolillo DJ; Cohen DJ; Sharma SK; Nicolas J; Briguori C; Cha JY; Collier T; Dudek D; Džavik V; Escaned J; Gil R; Gurbel P; Hamm CW; Henry T; Huber K; Kastrati A; Kaul U; Kornowski R; Krucoff M; Kunadian V; Marx SO; Mehta S; Moliterno D; Ohman EM; Oldroyd K; Sardella G; Sartori S; Shlofmitz R; Steg PG; Weisz G; Witzenbichler B; Han YL; Pocock S; Gibson CM; Mehran R
Eur Heart J; 2020 Oct; 41(37):3533-3545. PubMed ID: 33085967
[TBL] [Abstract][Full Text] [Related]
19. Design and Rationale of the BIOFLOW-DAPT Trial: a Prospective, Randomized, Multicenter Study to Assess the Safety of the Orsiro Mission Stent Compared to the Resolute Onyx Stent in Subjects at High Risk for Bleeding in Combination with 1-Month Dual Antiplatelet Therapy.
Landi A; Wlodarczak A; Tölg R; Kelbæk H; Legutko J; Galli S; Godin M; Toth GG; Lhermusier T; Honton B; Dietrich PL; Stammen F; Ferdinande B; Silvain J; Capodanno D; Cayla G; Valgimigli M;
J Cardiovasc Transl Res; 2023 Oct; 16(5):1135-1143. PubMed ID: 37264295
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive ascertainment of bleeding in patients prescribed different combinations of dual antiplatelet therapy (DAPT) and triple therapy (TT) in the UK: study protocol for three population-based cohort studies emulating 'target trials' (the ADAPTT Study).
Pufulete M; Harris J; Sterne JAC; Johnson TW; Lasserson D; Mumford A; Doble B; Wordsworth S; Benedetto U; Rogers CA; Loke Y; Pithara C; Redwood S; Reeves BC
BMJ Open; 2019 Jun; 9(6):e029388. PubMed ID: 31167875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
